Information on the Target

Templewater, a prominent private equity firm with a focus on mid-market control buyout opportunities in the Asia Pacific, has announced that its portfolio company, TW Pengu Holdings Limited (TWPHL), has successfully acquired Singapore Breast Surgery Center (SBSC), Central Luzon Integrated Oncology Centre (CLIOC), and Can-Care from TE Asia Healthcare, a pan-Asian healthcare services provider. These acquisitions are aimed at establishing TWPHL as a leading oncology group in Asia.

SBSC, founded in 2020, is an integrated breast cancer care facility in Singapore, offering comprehensive services throughout the entire breast cancer theragnostic process, including screening, diagnostic imaging, pathology, and surgery through its brands Solis and Luma. CLIOC, established in 2017, is an oncology clinic located in the Mother Teresa of Calcutta Medical Center in San Fernando, Philippines, providing advanced tomotherapy and chemotherapy services. Can-Care has been serving the market since 1997, specializing in personalized post-cancer care products and operating four retail outlets across Singapore and Malaysia.

Industry Overview in the Target’s Specific Country

The healthcare industry in Singapore is renowned for its high standards and advanced medical practices. As one of the leading healthcare hubs in Asia, Singapore's healthcare system is characterized by its strong regulatory framework, significant investment in technology, and a highly skilled workforce. The nation effectively integrates public and private healthcare services, ensuring comprehensive patient care.

Breast cancer is one of the most prevalent cancers in Singapore, necessitating specialized care systems to manage treatment and recovery effectively. With a growing aging population and increasing lifestyle-related health concerns, the demand for specialized oncology services is expected to rise. Innovative care solutions and advanced treatment options are paramount in addressing these needs.

In the Philippines, the oncology healthcare sector has been evolving, with a shift towards more patient-centric approaches and advanced technological interventions such as tomotherapy. The Central Luzon region, where CLIOC is located, has seen a growing demand for cancer care services due to increasing awareness and early detection initiatives. The integration of modern healthcare practices is vital for enhancing patient outcomes in oncology.

The post-cancer care market, represented by Can-Care, is equally crucial as it provides essential support to cancer survivors, a demographic that requires tailored services to navigate their recovery efficiently. This aspect of the industry highlights the importance of holistic cancer care throughout the treatment trajectory.

The Rationale Behind the Deal

This acquisition aligns with TWPHL's strategic vision of becoming a premier oncology care group in Asia. By integrating SBSC, CLIOC, and Can-Care into its portfolio, TWPHL aims to create a comprehensive oncology solution that spans the entire patient journey from diagnosis to recovery. The intent is to attract leading doctors and practices across multiple jurisdictions, thereby enhancing service delivery and improving patient outcomes.

Supported by Templewater’s commitment to investment in innovative healthcare solutions, TWPHL is positioned to redefine oncology care standards in the region. The firm’s investment will facilitate the expansion of TWPHL’s services and technology, ultimately benefiting a broad spectrum of oncology patients.

Information About the Investor

Templewater Group, founded in 2018 and headquartered in Hong Kong, is an alternative asset management firm that specializes in mid-market control buyout opportunities throughout the Asia Pacific. The group offers investment solutions across various asset classes, including private equity, impact investing, and real estate.

Templewater’s approach emphasizes collaboration with management teams to implement best practices and value-creation strategies. By focusing on growth-oriented investments, Templewater seeks to help portfolio companies achieve their maximum potential and deliver substantial returns for investors. Their track record includes building strong partnerships, which enhances their capability to foster innovation and operational excellence in funded companies.

View of Dealert

This recent consolidation within the oncology sector through the acquisition of SBSC, CLIOC, and Can-Care is a strategic and timely move by TWPHL. Given the growing demand for specialized cancer care services due to rising incidence rates and the critical need for post-treatment support, these acquisitions have the potential to significantly enhance TWPHL’s market position in Asia.

Moreover, the synergy between these acquisitions allows TWPHL to offer a full spectrum of oncology services, from diagnosis and treatment to recovery and supportive care. This comprehensive approach not only meets patient needs but also sets the stage for TWPHL to attract and retain top talent in the healthcare sector, as practitioners increasingly seek environments that promote comprehensive patient care.

Ultimately, Templewater's backing positions TWPHL to harness its capabilities to innovate and improve upon existing service offerings, potentially revolutionizing the oncology care landscape in the Asia Pacific. Thus, this deal is viewed as a promising investment, capable of delivering significant returns while contributing positively to patient care outcomes across the region.

View Original Article